Clinical trial / 2014
In patients with type 2 diabetes, daily resveratrol increased skeletal muscle SIRT1 expression and resting metabolic rate but reduced daily physical activity.
Ten subjects with type 2 diabetes mellitus were randomized to receive 3 g resveratrol or placebo daily for 12 weeks. Compared with placebo, resveratrol significantly increased skeletal muscle SIRT1 expression (2.01 vs. 0.86 AU, p = .016) and the p-AMPK to AMPK ratio (2.04 vs. 0.79 AU, p = .032). Resveratrol also increased the percentage absolute change in resting metabolic rate (8.6 vs. -13.9%, p = .033) and percentage of predicted resting metabolic rate (7.8 vs. -13.9%, p = .013), but caused significant reductions in average daily activity (-38 vs. 43.2%, p = .028) and step counts (-39.5 vs. 11.8%, p = .047).
- Study type
- Double-blind randomized controlled trial
- Who was studied
- 10 subjects with type 2 diabetes mellitus
- What was measured
- Skeletal muscle SIRT1 expression and energy expenditure
THE PAPER
Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure.
Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF. Int J Sport Nutr Exerc Metab, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.